Kroon Paul A, Clifford Michael N, Crozier Alan, Day Andrea J, Donovan Jennifer L, Manach Claudine, Williamson Gary
Nutrition Division, Institute of Food Research, Norwich, United Kingdom.
Am J Clin Nutr. 2004 Jul;80(1):15-21. doi: 10.1093/ajcn/80.1.15.
Human intervention studies have provided clear evidence that dietary polyphenols (eg, flavonoids--eg, flavonols--and isoflavones) are at least partly absorbed and that they have the potential to exert biological effects. Biological activity of polyphenols is often assessed by using cultured cells as tissue models; in almost all such studies, cells are treated with aglycones or polyphenol-rich extracts (derived from plants and foods), and data are reported at concentrations that elicited a response. There are 2 inherent flaws in such an approach. First, plasma and tissues are not exposed in vivo to polyphenols in these forms. Several human studies have identified the nature of polyphenol conjugates in vivo and have shown that dietary polyphenols undergo extensive modification during first-pass metabolism so that the forms reaching the blood and tissues are, in general, neither aglycones (except for green tea catechins) nor the same as the dietary source. Polyphenols are present as conjugates of glucuronate or sulfate, with or without methylation of the catechol functional group. As a consequence, the polyphenol conjugates are likely to possess different biological properties and distribution patterns within tissues and cells than do polyphenol aglycones. Although deconjugation can potentially occur in vivo to produce aglycone, it occurs only at certain sites. Second, the polyphenol concentrations tested should be of the same order as the maximum plasma concentrations attained after a polyphenol-rich meal, which are in the range of 0.1-10 micromol/L. For correct interpretation of results, future efforts to define biological activities of polyphenols must make use of the available data concerning bioavailability and metabolism in humans.
人体干预研究已提供明确证据,表明膳食多酚(如黄酮类化合物——如黄酮醇——和异黄酮)至少有部分会被吸收,且它们具有发挥生物学效应的潜力。多酚的生物活性通常通过使用培养细胞作为组织模型来评估;在几乎所有此类研究中,细胞都用糖苷配基或富含多酚的提取物(源自植物和食物)进行处理,并在引发反应的浓度下报告数据。这种方法存在两个固有缺陷。首先,血浆和组织在体内不会接触到这些形式的多酚。多项人体研究已确定了体内多酚共轭物的性质,并表明膳食多酚在首过代谢过程中会发生广泛修饰,因此到达血液和组织的形式通常既不是糖苷配基(绿茶儿茶素除外),也与膳食来源不同。多酚以葡萄糖醛酸或硫酸盐的共轭物形式存在,儿茶酚官能团可能有或没有甲基化。因此,多酚共轭物在组织和细胞内可能具有与多酚糖苷配基不同的生物学特性和分布模式。尽管体内可能会发生去共轭作用以产生糖苷配基,但它仅在某些部位发生。其次,所测试的多酚浓度应与富含多酚的膳食后达到的最大血浆浓度处于同一数量级,即0.1 - 10微摩尔/升的范围。为了正确解释结果,未来确定多酚生物活性的工作必须利用有关人体生物利用度和代谢的现有数据。